Marshall Wace, LLP Gilead Sciences, Inc. Put Options Transaction History

Marshall Wace, LLP

6 transactions

Quarter	Operation	Price Per put	puts change	puts Held
Q2 2023 Aug 14, 2023	BUY	$76.01 - $86.7 $14.5 Million - $16.6 Million	191,200 New	191,200 $14.7 Million
Q4 2022 Feb 14, 2023	BUY	$62.32 - $89.47 $186,960 - $268,410	3,000 Added 8.72%	37,400 $3.21 Million
Q3 2022 Nov 14, 2022	BUY	$59.54 - $68.01 $2.05 Million - $2.34 Million	34,400 New	34,400 $2.12 Million
Q4 2021 Feb 14, 2022	SELL	$64.88 - $73.64 $2.97 Million - $3.37 Million	-45,700 Reduced 43.4%	59,600 $4.33 Million
Q3 2021 Nov 15, 2021	BUY	$67.69 - $73.03 $6.02 Million - $6.49 Million	88,900 Added 542.07%	105,300 $7.36 Million
Q2 2021 Aug 13, 2021	BUY	$63.47 - $69.35 $1.04 Million - $1.14 Million	16,400 New	16,400 $1.13 Million

1,927

994M

10.5M

9.75M

Ticker GILD
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 1,253,369,984
Market Cap $114B
Description
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, a...

Get notified when there are updates to the investment portfolio of Marshall Wace, LLP, based on Form 13F filings with the SEC.

Stay updated on Marshall Wace, LLP with notifications on news.